A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia(2019)

引用 17|浏览9
暂无评分
摘要
The antiapoptotic protein myeloid cell leukemia sequence 1 (MCL-1) is highly expressed in many human cancers and has been implicated in the development of resistance to anti-cancer therapy. AMG 176 is a novel, selective, small molecule MCL-1 inhibitor. Here we report preliminary results from a phase 1, first-in-human trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of AMG 176 in relapsed or refractory multiple myeloma (RRMM).
更多
查看译文
关键词
Mcl-1 inhibitor,Pharmacokinetics,Tolerability
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要